Pathological Mobilization and Activities of Dendritic Cells in Tumor-Bearing Hosts: Challenges and Opportunities for Immunotherapy of Cancer by Amelia J. Tesone et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW ARTICLE
published: 10 December 2013
doi: 10.3389/fimmu.2013.00435
Pathological mobilization and activities of dendritic cells in
tumor-bearing hosts: challenges and opportunities for
immunotherapy of cancer
Amelia J.Tesone1, Nikolaos Svoronos1,2, Michael J. Allegrezza1,2 and Jose R. Conejo-Garcia1*
1 Tumor Microenvironment and Metastasis Program,Wistar Institute, Philadelphia, PA, USA
2 Cell and Molecular Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Edited by:
Timothy Bullock, University of Virginia,
USA
Reviewed by:
AlexYee-Chen Huang, CaseWestern
Reserve University School of
Medicine, USA
Luis De La Cruz-Merino, Hospital
Universitario Virgen Macarena, Spain
*Correspondence:
Jose R. Conejo-Garcia, Tumor
Microenvironment and Metastasis
Program,Wistar Institute, 3601
Spruce Street, Philadelphia, PA
19104, USA
e-mail: jrconejo@wistar.org
A common characteristic of solid tumors is the pathological recruitment of immunosup-
pressive myeloid cells, which in certain tumors includes dendritic cells (DCs). DCs are of
particular interest in the field of cancer immunotherapy because they induce potent and
highly specific anti-tumor immune responses, particularly in the early phase of tumorigene-
sis. However, as tumors progress, these cells can be transformed into regulatory cells that
contribute to an immunosuppressive microenvironment favoring tumor growth.Therefore,
controlling DC phenotype has the potential to elicit effective anti-tumor responses while
simultaneously weakening the tumor’s ability to protect itself from immune attack. This
review focuses on the dual nature of DCs in the tumor microenvironment, the regulation
of DC phenotype, and the prospect of modifying DCs in situ as a novel immunotherapeutic
approach.
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INTRODUCTION
Accumulated experimental and clinical evidence indicate that the
immune system recognizes neoplasms and attempts to mount a
response against these altered cells. However, immune pressure
against established tumors is clearly not sufficient to defend
tumor-bearing hosts from disease progression, and eventually
death. A universal occurrence in established tumor-bearing indi-
viduals is a profound alteration of myelopoiesis (1). Pathological
myeloid differentiation leads to the expansion of a heterogeneous
population of immunosuppressive myeloid cells that accumulates
in the spleen and gives rise to regulatory macrophages and den-
dritic cells (DCs) in tumors (2). This diverse mix of pathological
myeloid cells at different stages of differentiation (generically
termed Myeloid-Derived Suppressor Cells, or MDSCs) is highly
immunosuppressive (1, 3). MDSCs also contribute to enhanced
angiogenesis (4), as well as the formation of metastatic niches
for malignant dissemination (5, 6). Additionally, defective devel-
opment alters the critical function of myeloid cells that, under
normal physiological conditions, would terminally differentiate
into DCs, macrophages, or neutrophils. Defective myleopoiesis
results in a significant defect in antigen presentation, which
is aggravated during malignant progression, and drives T cell-
intrinsic transcriptional programs that promote T cell anergy
and exhaustion. In contrast, certain tumors mobilize excessive
amounts of lineage-committed, classical CD11c+ DCs that, rather
than driving tumor antigen-specific responses, impair T cell effec-
tor function at the tumor bed. Here, we will review how patho-
logical myelopoiesis and tumor microenvironmental networks
progressively abrogate the immunostimulatory function of DCs,
resulting in unresponsive T cells and prevention of the lingering
immune pressure exerted by remaining tumor-reactive lympho-
cytes. We will conclude by discussing potential approaches to
overcome these effects in vivo and in situ.
TUMORS PROMOTE DEFECTIVE DC DIFFERENTIATION AND
MATURATION
Dendritic cells originate in the bone marrow from the differentia-
tion of hematopoietic precursors to Common Myeloid Progenitors
and subsequently to DCs. Recent evidence indicates that, at least in
mice, precursors of conventional DCs specifically express Clec9a
and represent an independent lineage much less dependent on
inflammation-induced monocyte differentiation than previously
thought (7).
A hallmark of virtually all solid tumors is aberrant expansion
of pathologically differentiated myeloid leukocytes (see Table 1).
These cells arise from myeloid progenitors under the influence of
inflammatory signals (8) and accumulate at splenic, lymphatic,
and tumor locations. While they retain an immature pheno-
type, these MDSCs are highly immunosuppressive (9). Elegant
experiments based on transfer of tumor-derived MDSCs of the
myelomonocytic lineage have shown that under the influence of
hypoxia in the tumor microenvironment (TME), these altered
precursors of macrophages and DCs still reach their termi-
nally differentiated cell fates (2). However, as expected from
the succession of non-physiological signals that these myeloid
cells receive, their phenotype is quite different from canonical
macrophages and DCs generated under steady state conditions
(see Figure 1). Tumor-differentiated macrophages, for instance,
retain an immunosuppressive phenotype that contributes to
accelerate malignant progression.
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Table 1 | Phenotypic features of different tumor-infiltrating myeloid cell populations.
Cell type Other
names
Surface markers Chemokine
receptors
Phenotype Human tumors
observed within
Reference
MDSC CD11b+GR-1+ (m),
Lin-CD33+MHC-II− or
CD11b+CD33+CD14− (h)
Immunosuppressive Breast, renal-cell,
pancreatic, melanoma,
head and neck
Gabrilovich and Nagaraj (9)
Mature
DC
Classical
DC
CD11c+MHC-IIhigh CCR7,
CXCR4
Immunostimulatory
Immature
DC
CD11c+MHC-IIlow CCR6, CCR2,
CXCR4
Antigen uptake,
Immunosuppres-
sion
Ovarian, breast, lung,
colorectal, melanoma,
renal-cell, prostate
Chaux et al. (10),
Pinzon-Charry et al. (11),
Perrot et al. (12)
Pre-DC CD11c+MHC-II− CCR1, CCR5,
CCR2
Committed to DC
lineage
Regulatory
DC
Tolerogenic
DC
CD11c+CD11b±,
MHC-II+CD86highPD-L1+
CXCR4,
CCR6
Immunosuppressive Cervical, hepatocellular,
breast, ovarian
Lee et al. (13), Ormandy
et al. (14), Pinzon-Charry
et al. (15), Scarlett et al. (16)
Mouse and human markers are indicated by (m) and (h), respectively.
In dissecting the role of DCs in cancer, most studies have
focused on impaired DC differentiation as the cause of diminished
production of mature, functionally competent DCs (1, 19). In
support of this concept, a decrease in the accumulation of mature
DCs has been found in patients with cervical (13), hepatocellular
carcinoma (14), lung (12), colorectal (10), and breast cancer (15).
Blockade of DC differentiation in tumor-bearing hosts was pri-
marily attributed to VEGF, a common tumor microenvironmental
factor widely known for its role in promoting tumor angiogenesis
(20, 21). Accordingly, VEGF levels negatively correlate with the
number of DCs in the blood or tumor in a variety of human can-
cers (22–24). These studies implied that the paucity of functionally
mature DCs in tumors was a major contributing mechanism to
overall immune evasion.
The consequence of defective antigen presentation in cancer
individuals is T cell unresponsiveness, which may be the result
of anergy or exhaustion. Unlike replicative senescence, anergy
and exhaustion are reversible processes that result from different
transcriptional programs but are frequently confused (25, 26).
Anergy takes place at the time of priming, while exhaustion
occurs in previously activated T cells undergoing repeated expo-
sure to suboptimal amounts of antigen in the presence of neg-
ative costimulation. As emerging clinical evidence using PD-1
inhibitors suggests, T cell exhaustion is a major driver of tumor-
induced immunosuppression in more than a third of cancer
patients (27, 28).
TUMORS ALSO INDUCE THE ACCUMULATION OF FULLY
COMMITTED DCs WITH IMMUNOSUPPRESSIVE ACTIVITY
While impaired DC differentiation and maturation may explain
the myeloid phenotypes found in some tumors, they do not
explain the accumulation of DCs with regulatory phenotypes
that we and others have found in certain tumors (16, 29). Thus,
we showed that classical DCs with immunosuppressive activity,
termed regulatory DCs, accumulate in the TME. In tumors,
these DCs suppress T cell effector functions through multiple
mechanisms that include the expression of PD-L1, the production
of l-Arginase and the up-regulation of tolerogenic butyrophilins
(16, 30–38). The contribution of classical DCs to tumor-induced
immunosuppression is therefore different from the mere lack of
fully differentiated, immunostimulatory DCs, at least in certain
carcinomas (see Table 1).
Because the myeloid leukocytes that are found in the TME
represent a heterogeneous mix of abnormal cells at different stages
of differentiation, phenotypic overlap and variability between
patients hinder a conclusive categorization of macrophages vs.
differentiated DCs vs. more immature precursors across tumor
specimens. Nevertheless, we have demonstrated that the pre-
dominant population infiltrating solid human ovarian cancer
specimens (but not human ascites) exhibits predominant deter-
minants of DCs, including CD11c, HLA-DR, and DEC205, but
do not express the monocyte/macrophage markers CD11b or
CD14 in at least 1/3 of patients (16). Irrespective of nomen-
clature in human tumors, we have also demonstrated that the
counterpart of this population in ovarian cancer mouse mod-
els can be induced to process full-length OVA in vitro (30) and
in vivo (32, 34), and effectively present processed SIINFEKL to
T cells in response to certain activating signals. These CD11c+
cells also produce Zbtb46 transcripts (39, 40) and express Clec9a
(7) further implying their DC nature. DCs are therefore impor-
tant players of the immunosuppressive networks orchestrated by
at least some frequent epithelial tumors, and defective antigen-
presenting activity contributes to the abrogation of the protective
function of anti-tumor T cells.
We initially assumed that these DCs were “immature,” and
therefore simply unable to prime T cell responses. However,
ovarian cancer DCs express significant levels of CD86. Even
more surprisingly, human tumor DCs in multiple specimens also
express CD83, an activation marker. Furthermore, these DCs
produce high levels of inflammatory cytokines such as IL-6 and
the chemokine CCL3 (32–34). Additionally, although TLR acti-
vation can further up-regulate MHC-II, these DCs express rela-
tively high MHC-II levels in the TME, in both humans and mice
(16, 37). Most importantly, progressive weakening of anti-tumor
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FIGURE 1 | Pathological dendritic cell differentiation contributes to
tumor-induced immune evasion. Cancer-associated inflammation
up-regulates the production of myeloid cells from hematopoietic progenitors
in the bone marrow. Common myeloid progenitor cells give rise to
pre-dendritic cells (pre-DCs) and, under the influence of tumor-derived factors
(e.g., VEGF, IL-6, and S100A9), myeloid-derived suppressor cells (MDSCs).
These myeloid cells migrate into the tumor microenvironment in response to
chemokines such as CCL3, CCL12, CXCL12, and β-Defensins. VEGF and IL-6
activate STAT3 and C/EBPβ signaling in MDSCs, keeping them in an immature
phenotype characterized as CD11b+Gr-1+ in mice and LIN−CD33+MHC-II− or
CD11b+CD33+CD14− in humans. Additionally, IL-6, IL-10, and the accumulation
of lipids can activate p38 MAPK signaling to prevent the acquisition of classic
DC function. Also, some MDSCs can differentiate into DCs in the hypoxic
environment of the tumor. Immature DCs (iDCs) exhibit low NF-κB activation,
express CD11c in mice and humans, and have low MHC-II levels. These iDCs
are defective antigen presenters, which induces T cell anergy and exhaustion.
In other conditions, like those found in epithelial ovarian cancer, pre-DCs
mature into cells that express markers of conventional DCs (CD11c+
MHC-II+CD86high), but exert immunosuppressive functions, termed regulatory
DCs (Reg DCs). Factors such as TGF-β, PGE2, IL-4, and retinoic acid have been
shown to promote this altered maturation. These Reg DCs differ from
conventional DCs in their ability to suppress effector T cell function through
multiple mechanisms, which include: (1) secretion of the enzymes L-Arginase
and IDO that result in the depletion of essential amino acids and production of
the tolerogenic metabolites adenosine and kynurenine; (2) release of
immunosuppressive factors such as IL-10 and TGF-β; (3) expression of
costimulatory surface molecules, including PD-L1 and butyrophilins, that
negatively regulate anti-tumor T cells; (4) induction of regulatory T cells
(Tregs). More information regarding the source of the various secreted factors
that govern the accumulation and function of tumor-associated myeloid cells
can be found in recent reviews by Hanahan and Weinberg as well as
Lindau et al. (17, 18).
immunity cannot be solely attributed to “scarcity” of mature DCs
in these tumors because depleting DCs at advanced stages of malig-
nant progression in preclinical models paradoxically delays tumor
growth, rather than being simply “neutral” (16). Excessive accu-
mulation of immunosuppressive DCs, rather than mere absence
of immunostimulatory antigen-presenting cells (APCs), is there-
fore the predominant mechanism of DC dysregulation in at least
ovarian carcinoma.
These regulatory DCs are also different than their immature
precursors due to their main location of action. Immature DCs
that fail to efficiently activate T cells in the lymph node will pri-
marily prevent T cell priming, leading to anergy or tolerization.
And while we have identified immunosuppressive, regulatory DCs
in the draining lymph node (16), the remarkable suppression
by tumor-infiltrating DCs contributes to a protective barrier for
tumor cell growth. By suppressing effector T cells through many
mechanisms we discuss here, tumor-infiltrating DCs can effec-
tively shut down activated anti-tumor immune responses. This
important difference has imperative consequences for the fate of
therapies that rely solely on eliciting tumor-directed T cells. For
this reason, we mostly focus on the action of these altered DCs
inside the tumor in this review.
Based on our converging evidence, we propose that regula-
tory DCs in tumors are not immature, but acquire an alternative
phenotype in response to a different transcriptional program.
Some peculiarities of this aberrant program have been identi-
fied in our recent studies. Thus, we demonstrated that delivery of
synthetic (and functional) microRNA-155 (miR-155) specifically
www.frontiersin.org December 2013 | Volume 4 | Article 435 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tesone et al. Tumor-induced dendritic cell dysfunction
to CD11c+DEC205+MHC-II+ DCs in the microenvironment
of ovarian cancer-bearing mice induced genome-wide transcrip-
tional changes that were sufficient to transform these immuno-
suppressive leukocytes into an immunostimulatory cell type (37).
Compared to the delivery of non-targeting double-stranded RNA
of similar length and structure, ectopic miR-155 induced silencing
of multiple immunosuppressive mediators, including Tgfb1 and
Cd200. As expected, miR-155 also targeted crucial transcription
factors involved in aberrant myeloid differentiation in tumor-
bearing hosts, including Cepb/β and Socs1. Most importantly,
miR-155 activity down-regulated Stat3 and, interestingly, Satb1, a
master genomic organizer (37,41). Unexpectedly,however, expres-
sion of miR-155 also silenced the expression of Pu.1/Sfpi1 and
Irf8 (>150-fold in both cases) (37). This is significant because
PU.1 promotes DC differentiation by inducing the remodeling of
the higher-order chromatin structure at the Irf8 gene. Therefore,
myeloid IRF8 expression depends on high PU.1 levels (42). Most
importantly, DC commitment requires active IRF8 to avoid alter-
native myeloid-lineage differentiation (42). The fact that synthetic
miR-155-expressing DCs acquire the capacity to effectively present
antigens in vivo and in vitro suggests that they were fully commit-
ted to a DC phenotype, albeit transcriptionally different from their
classical immunostimulatory counterparts.
TUMOR- AND STROMA-DERIVED CHEMOATTRACTANTS
DRIVE DC RECRUITMENT TO TUMOR LOCATIONS
The presence of regulatory DCs, as opposed to simply immature
precursors, in the microenvironment of different tumors can be
partially driven by the abundance and repertoire of tumor- and
stroma-derived chemokines and cytokines, which is dependent on
differential DC expression of chemokine receptors (43–45). For
instance, the chemokine CCL3, aberrantly up-regulated in many
tumors, enhances pre-DC recruitment in both in vitro and in vivo
models of melanoma, colon, and lung carcinoma. Moreover, CCL3
preferentially recruits pre-DCs to tumor locations, as antibody
mediated neutralization of CCL3 does not result in a decrease
in any other CD45+ leukocyte subset, nor does it alter the fre-
quency of splenic pre-DCs (46). Furthermore, pre-DC expression
of CCR1 and CCR5 provide a mechanism for CCL3-mediated
recruitment (47). In addition, tumor hypoxia, which characterizes
a wide variety of TMEs, also triggers DC and immature myeloid
cell recruitment via tumor-derived CCL12.
Additionally, tumor microenvironmental prostaglandin E2
(PGE2) up-regulates the chemokine CXCL12, thereby accumulat-
ing CXCR4-expressing regulatory DCs (48, 49). Another relatively
uninvestigated factor that promotes the recruitment of CCR6+
regulatory DCs to tumor locations is the expression of β-Defensins
by epithelial cells and inflammatory leukocytes. In preclinical
models, ectopic tumor expression of Defb29 has been shown
to accelerate the accumulation of DCs in the TME, leading to
more aggressive malignant progression (30). Defensins are clearly
powerful chemoattractants (50) that are expressed at significantly
higher levels in certain cancer patients (51).
Perhaps the most compelling evidence that tumor-derived
chemokines influence the type of DCs found in the tumor has
been demonstrated in a renal-cell carcinoma model (52),where the
intra-tumoral or peri-tumoral distribution of DCs is determined
by CCL20 and CCL19 levels. High intra-tumoral levels of CCL20
result in the accumulation of immature CCR6+ DCs within the
tumor bed, whereas high peri-tumoral levels of CCL19 promote
the accumulation of mature CCR7+ DCs preferentially to the
tumor margin.
PATHWAYS PREVENTING DENDRITIC CELL
DIFFERENTIATION
The accumulation of immature DCs and earlier progenitors are
also the result of corrupted pathways of inflammation-driven
myeloid differentiation. The extent of the corrupted nature of
myelopoiesis in cancer has been underscored by recent studies by
Gabrilovich and colleagues showing that the epigenetic silencing
of the retinoblastoma gene in immature (non-tumor) myeloid
cells is sufficient to drive transdifferentiation of myelomonocytic
MDSCs to granulocytic MDSCs (53). A block in the differen-
tiation of immature myeloid precursors into mature myeloid
cells results in fewer DCs and an accumulation of MDSCs. The
molecular pathways driving this process are known to be STAT3-
dependent. For instance, high STAT3 activity has been shown
to inhibit both the differentiation of mature DCs from myeloid
precursors (54) and the activation and MHC-II up-regulation of
DCs (55). Still, the molecular mechanism of this STAT3 signaling
remains incompletely understood. Studies by Lee and colleagues
have shown that tumors mediate both STAT3 activation and PKC
βII down-regulation in DC progenitor cells (56). Importantly, PKC
βII repression can be mimicked by the expression of a constitu-
tively active STAT3 mutant. Because PKC βII is required for DC
differentiation (57), these reports have identified a roadblock for
subsequent maturation of myeloid precursors, but more studies
are needed to fully dissect this mechanism.
Many factors overexpressed in the tumor macro- and microen-
vironments promote STAT3 activation. It has been demonstrated
that the negative effect of tumor conditioned media on DC
activation could be reversed by using either STAT3 null DCs
or DCs treated with a peptide inhibitor of STAT3 (58). Some
mediators of this process include IL-6, IL-10, and VEGF, which
are generally increased systemically in cancer patients and nega-
tively correlate with prognosis (59). The STAT3 activator IL-6 is
particularly important for the development of functionally defec-
tive DCs (60). Tumor-derived IL-6 drives STAT3 nuclear transloca-
tion in immature myeloid cells, thus promoting proliferation and
inhibiting apoptosis of MDSCs. Furthermore, IL-6 and M-CSF
secreted by human renal carcinoma cell lines inhibit DC differen-
tiation from CD34+ bone marrow progenitors (61). In addition,
STAT3 up-regulates S100A9 in hematopoietic progenitor cells,
which inhibits further differentiation to DCs and retains these
cells as MDSCs, leading to tumor tolerance (62).
Besides STAT3, some of these cytokines inducing MDSCs also
act on a common molecular pathway that is entirely dependent on
the C/EBPβ transcription factor. C/EBPβ is therefore required for
the immunoregulatory activity of both tumor-induced and bone
marrow-derived MDSCs (63).
Additionally, VEGF has been shown to impair DC differentia-
tion from progenitors through the inhibition of another pathway
that is also important for DC maturation; namely, by preventing
NF-κB activation (21, 64).
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PATHWAYS PREVENTING DENDRITIC CELL MATURATION
Besides impairment of DC development, DCs can be found
in an active immature phenotype associated with induction of
peripheral tolerance. Numerous studies have demonstrated that
these immature DCs (iDCs) are unable to support normal lev-
els of antigen-specific T cell expansion. For example, human
monocyte-derived DCs (mo-DCs) are unable to induce expan-
sion of antigen-specific, tetramer-positive T cells when kept in
an immature phenotype by differentiation in the presence of
the adenosine receptor agonist NECA or cAMP elevating agents
FSK/IBMX (65).
Under steady state conditions, DCs exist in an immature
state characterized by high phagocytic activity and low
antigen-presenting capabilities. Upon being activated by innate
pathogen or damage associated signals, DCs acquire a mature state
characterized by MHC presentation of antigens and costimulatory
signaling via B7 family molecules (e.g., CD80 and CD86). For an
immature DC to become an efficient APC, it must receive specific
activating signals through receptors such as CD40, TNF-R, IL-1R,
and TLRs (66). Although the intricacies of how DC maturation
is blocked remain to be fully dissected, an important mechanism
preventing DC maturation appears to be mediated by the p38
MAPK pathway. IL-6, IL-10, and TGF-β contained in myeloma-
conditioned media have been shown to activate this pathway and
prevent the immunostimulatory activity of immature DCs. Abro-
gating p38 MAPK with a small molecule inhibitor during DC
development enhanced their subsequent activation, making them
more mature and stimulatory even when differentiated in the con-
ditioned media (67). In addition, paclitaxel-induced inhibition of
p38 MAPK activity decreases the production of S100A9 and TNF-
α by MDSCs, resulting in reduced tumor burden and increased
animal survival (68). In tumor-bearing mice, paclitaxel induces the
maturation-dependent antigen-presenting activity of DCs (69).
High levels of IL-10 in tumor-bearing hosts also impair the
complete maturation of DCs. DCs from mice that overexpress
IL-10 have low expression of MHC-I and costimulatory molecules
and are deficient at stimulating T cell responses (70). Accordingly,
IL-10 treated human DCs induce anergy in T cells, although
fully matured DCs were resistant to the effect of IL-10 (71).
Pancreatic tumor cells were also found to secrete IL-6 and IL-10
thus suppressing the stimulatory abilities of DCs in allogeneic
reactions (72).
Another pathway relevant for effective DC maturation is depen-
dent on NF-κB activation. Signaling via NF-κB is required for
the professional APC function of DCs, including high expression
of MHC-II and costimulatory molecules, secretion of IL-12 and
TNFα, and stimulation of allogeneic T cells (73). Recently, PD-
1 expression on DCs from murine ovarian tumors was found
to decrease NF-κB activation, resulting in less production of
inflammatory cytokines (74).
Additional mechanisms that remain poorly understood but
could be very important for preventing the immunostimula-
tory potential of tumor-associated DCs are dependent on how
myeloid leukocytes metabolize lipids in the TME. Tumor DCs
up-regulate scavenger receptor A (SR-A), a target used for ther-
apeutic depletion of regulatory DCs in preclinical models (75).
Overexpression of SR-A increases the uptake of extracellular lipids,
which are pathologically accumulated in DCs (76). Tumor DCs
from mice and humans were demonstrated to have relatively high
levels of triglycerides that impaired their ability to process antigen,
and could be functionally restored upon normalization of their
triglyceride levels.
Finally, immunomodulatory signals can also come from
metabolites, as tumor-derived lactate can skew the differentiation
of human monocytes into less mature DCs (defined by less CD1a
expression) that are deficient in their ability to stimulate T cells
and secrete IL-12 (77).
PATHWAYS DRIVING THE TRANSFORMATION OF DENDRITIC
CELLS INTO AN IMMUNOSUPPRESSIVE CELL TYPE
In addition to blocking DC differentiation and full activation,
the TME also contains multiple factors that transform classical
DCs with antigen-presenting capabilities into immunosuppressive
players. Our recent studies in a preclinical model of sarcoma-
toid carcinoma in immunocompetent mice have illustrated that
this switch takes place during malignant progression (16, 37).
In this system, the inflammatory microenvironment of advanced
tumors recapitulates the molecular and cellular components of
immune cells found in human solid tumors. We found that at ini-
tial stages of tumor development, DCs elicit T cell responses that
are able to put tumor growth in check for relatively long periods.
As expected, depleting DCs at early stages of tumor progression
resulted in accelerated tumor progression, which mimicked T cell
depletion. However, as these tumors advanced, DC differentia-
tion was not blocked. Rather, CD11c+MHC-II+DEC205+ DCs
with regulatory activity started accumulating at tumor locations,
which coincided with the beginning of the exponential growth
phase of these latent tumors. Strikingly, DC depletion at this
advanced stage of malignant growth was sufficient to significantly
delay (rather than advance) malignant progression. DCs in these
late-stage tumors are therefore not simply immature or unable
to effectively present antigens. In fact, although DCs in advanced
tumors exhibited lower expression of MHC-II and costimulatory
CD40, they still expressed both at significant levels. Instead they
became active accomplices to tumor growth through the inhibition
of protective immunity.
Dendritic cell accumulation in solid tumors is not only found in
the microenvironment of solid ovarian carcinomas. For instance,
Norian et al. found that MHC-II+CD11b+CD11chigh DCs infil-
trating established mammary carcinomas could also act as regula-
tory players by inhibiting CD8 T cell function through l-Arginase
production, thus dampening T cell-mediated anti-tumor immune
protection (29). Naïve T cells primed with these DCs undergo min-
imal expansion and defective IFN-γ production, and eventually
become anergic. The phenotype of these regulatory DCs therefore
does not correspond to the plasmacytoid DC type that has been
traditionally associated with the development and maintenance
of immunosuppression, although these cells are also found in the
microenvironment of many tumors (78–81).
Among the potential tumor microenvironmental factors
driving the transformation of immunostimulatory DCs into
immunosuppressive players, we identified that at least PGE2 and
TGF-β (but not IL-6) in supernatants from primary cultures, are
both necessary to elicit a regulatory phenotypic switch in DCs
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from early tumors. These DCs were then capable of suppressing
the strong proliferation of tumor-reactive T cells in response to
tumor antigen presented by other DCs (16, 37).
In addition, IL-4 and retinoic acid synergize to induce the
expression of Aldh1a2 in GM-CSF-differentiated inflammatory
DCs, turning on their regulatory activity (82). Retinoic acid is also
known to enhance TGF-β-induced Smad3 activation (83), poten-
tially synergizing with the induction of suppressive features elicited
by TGF-β on DCs (16, 37).
Another important factor dampening the immunostimula-
tory potential of tumor DCs is kynurenine, the first product of
the tryptophan degradation pathway generated by Indoleamine-
pyrrole 2,3-dioxygenase (IDO) (84, 85). Kynurenine, by inter-
acting with the aryl hydrocarbon receptor (AHR), elicits an
autocrine loop in DCs, resulting in enhanced IDO activity and
the acquisition of an immunosuppressive phenotype by orig-
inally immunocompetent DCs (86). In another study, IDO
expression was found to be required for DC-induced toler-
ance, and, via TGF-β-induced expression of IDO, it was possi-
ble to convert CD8-negative DCs from being immunogenic to
regulatory (87).
MECHANISMS OF IMMUNOSUPPRESSION DRIVEN BY DC
SECRETION OF IMMUNOSUPPRESSIVE FACTORS
Regulatory DCs suppress immune responses by secreting anti-
inflammatory soluble factors that inhibit effector T cell functions
or skew T cell responses. DCs, for instance, are a major source
of IDO within the TME. DCs infiltrating multiple tumors show
enhanced IDO activity. For example, IDO-expressing FOXO3+
DCs were shown to promote malignant progression in preclinical
models of prostate cancer (88). Kynurenine produced by IDO acti-
vates AHR, which is central to T cell differentiation into FoxP3+
regulatory T cells (Tregs) (89, 90). Generation of induced Tregs is
not only a property of murine tumor DCs, as IDO expression in
human DCs also results in induction of Foxp3+, immunosuppres-
sive T cells when these DCs are co-cultured with healthy donor
CD3+ lymphocytes. This induction was confirmed to be IDO-
dependent by reversal of T cell phenotype following tryptophan
treatment (91).
Regulatory DCs, and not only macrophages or MDSCs, are
also important contributors to immunosuppression in the TME
through the production of l-Arginase (16, 29, 37). l-Arginase
activity results in catabolic depletion of Arginine, an amino acid
essential for effector T cells. Upon undergoing a phenotypic
switch from being immunostimulatory to immunosuppressive,
DCs found in advanced tumors significantly increase l-Arginase
activity. Importantly, freshly dissociated human ovarian carci-
noma specimens also contain DCs with significant l-Arginase
activity (16, 37).
Among the factors that enhance l-Arginase activity in the TME,
IL-6 is perhaps the best characterized. IL-6 treatment of bone
marrow-derived DCs (BMDCs) results in increased l-Arginase
RNA, protein, and activity both in vitro and in vivo. The conse-
quent drop in extracellular arginine resulted in down-regulation
of MHC-II in the same DCs and impaired ability to activate OT-II
T cells. These results were similarly reproduced by differentiating
BMDCs in arginine-free conditions (92).
Other immunosuppressive factors produced by DCs in
advanced tumors include cytokines such as TGF-β and IL-10.
Tumors induce DCs to secrete TGF-β, further promoting Treg
expansion and indirectly suppressing T cell effector functions
(93, 94). However, the relative contribution of DC-derived TGF-β
compared to the production of this cytokine by other microenvi-
ronmental cell types (e.g., certain T cell subsets, including Tregs),
needs to be comprehensively addressed.
MECHANISMS OF IMMUNOSUPPRESSION DRIVEN BY DCs
THROUGH MEMBRANE-BOUND DETERMINANTS
In addition to not providing sufficient antigen or costimulation,
tumor-associated DCs frequently express negative costimulatory
molecules that suppress T cell activity. As evidenced by the emerg-
ing success of novel clinical inhibitors, perhaps the most important
negative signaling is mediated through PD-L1:PD-1 interactions
(95). PD-1 is a negative costimulatory receptor primarily expressed
on activated lymphocytes. The most abundant ligand for PD-1,
B7-H1/PD-L1, is up-regulated in DCs and tumor cells in multiple
cancers. PD-1 itself can also be expressed by tumor DCs them-
selves, at least in murine models. Expression of the PD-L1:PD-1
pair was found to increase throughout malignant progression, cor-
relating with loss of positive costimulatory markers (CD80, CD86,
and CD40), a lack of cytokine release (IL-12, IL-10, IL-6, TNFα,
and G-CSF), and contact-dependent inhibition of T cell expansion
(74). Importantly, inhibitors for both the ligand (PD-L1) and the
receptor (PD-1) have been developed and have shown impressive
clinical results (27, 28). However, PD-1 blockers appear to be better
candidates for future FDA approval, while PD-L1 inhibitors appear
to produce better results in murine models (96), possibly related
to the affinity and pharmacokinetics of different humanized and
mouse-specific antibodies.
Aside from PD-L1, regulatory DCs can express other neg-
ative costimulatory molecules. One of these inhibitors, uni-
versally expressed in ovarian cancer-infiltrating DCs, is CD277
(35). CD277 identifies various highly similar members of the
butyrophilin subfamily 3 (BTN3). The function of these molecules
is poorly investigated, but they share sequence and structural
homology to the negative costimulatory molecule B7-H4. CD277
is expressed by CD45+ MHC-II+ APCs isolated from human
epithelial ovarian cancer samples, and is up-regulated in human
mo-DCs in response to molecules found in the TME, such as IL-6,
IL-10,VEGF, PIGF-1, and CCL3. We showed that CD277 expressed
in artificial APCs consistently decreased the expansion of TCR-
stimulated T cells. However, one of the butyrophilins expressing
the CD277 epitope (BTN3A1), has been recently reported as an
activating receptor (thus not a ligand) in γδ T cells, where it
binds phosphorylated antigens with low affinity (97). In addi-
tion, other similar molecules such as BTNL8 have been associated
with immunostimulatory activity when a soluble fusion protein
was used (98). It is unclear, however, whether the activity of buty-
rophilins depends on engagement of the unknown receptor in T
cells in a cross-linked or soluble form.
Also important for the generation of tolerogenic mediators
are the two ecto-enzymes CD39 and CD73 that act sequen-
tially to generate anti-inflammatory extracellular adenosine (72,
99, 100). Among the many suppression-promoting effects that
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TGF-β induces in DCs, it up-regulates the expression of CD73
(101). CD73 produces adenosine from AMP, which engages
with the adenosine A2A receptor (A2AR). A2AR ligation both
inhibits the expansion of effector T cells and promotes the
generation of induced Tregs (102). Chemical enzymatic inhibitors
or neutralizing antibodies targeting these ecto-enzymes therefore
offer novel promising avenues of therapeutic interventions.
IMPLICATIONS OF DC DYSREGULATION IN CANCER
PATIENTS FOR THERAPEUTIC DENDRITIC CELL-BASED
VACCINES
Because DCs are the most potent APCs, they have been used
to boost T cell-mediated immune protection against cancer for
nearly two decades. Multiple approaches have been shown to
work effectively in mice, primarily as prophylactic interventions.
However, any reproducible clinical benefit for patients with estab-
lished cancer has been marginal so far (103). It is true that there
is still room for improvement, especially regarding immunos-
timulatory cell type and route of administration. However, con-
verging clinical evidence suggests that quantifiable improvements
in immunological readouts are not associated with reproducible
clinical responses (104).
Although DC-based vaccines are designed to overcome defec-
tive maturation, challenges with migration to places of T cell
priming and, especially, the abrasive effect of the immunosuppres-
sive networks in the TME, have so far rendered vaccine-induced
T cell responses ineffective against tumor-induced tolerance. A
successful trial using autologous lysate-pulsed DC vaccination
in recurrent ovarian cancer has become an auspicious exception
(105). However, DC vaccination in this trial was followed by adop-
tive transfer of vaccine-primed, ex vivo stimulated T cells, and it
is therefore unclear whether the obvious clinical responses can be
at all attributed to the initial vaccine. Nevertheless, this approach
opens new avenues for the use of DCs for effective priming of
autologous tumor-reactive T cells ex vivo.
All the aforementioned mechanisms of DC dysfunction in
advanced malignancy contribute to our understanding of the
failure of DC vaccines to deliver on their original promise. Even if
ex vivo matured DCs could reach lymph nodes and can effectively
prime tumor antigen-specific T cells without being affected by
TFG-β, retinoic acid, or IDO metabolites, it is becoming increas-
ingly clear that anti-tumor T cells will succumb in the TME, unless
immunosuppression is concurrently targeted. Consequently, new
opportunities emerge from the use of DC-based vaccines to treat
early-stage disease, where they can be more efficacious in the
absence of systemic immune dysfunction (106). DC-based vac-
cines, for instance, are now being tested against ductal carcinoma
in situ (DCIS), to prevent development of subsequent breast can-
cer. Recent trials observed reduced recurrences in patients with
estrogen receptor negative DCIS. Because the immunosuppressive
networks are not as strong at this disease stage, this approach may
be more promising (107).
REVERSING THE PHENOTYPE OF DENDRITIC CELLS FROM AN
IMMUNOSUPPRESSIVE TO AN IMMUNOSTIMULATORY CELL
TYPE
While the establishment of regulatory DCs is a significant patho-
logical event in solid tumors, the central role that DCs play
in orchestrating adaptive immunity still offers opportunities for
therapeutic intervention that could have lasting benefit. In situ
vaccine-based interventions aimed at transforming tumor DCs
into activated APCs capable of priming host anti-tumor T cells
represent a promising approach to both actively boost T cells and
inhibit immunosuppression. Vicari and colleagues first reported
that tumor-infiltrating DCs are able to be rescued and become
effective tumor antigen presenters in the context of MHC-I, pro-
vided that they receive the right stimulatory signals. They found
that DCs were refractory to stimulation with the combination
of LPS, IFN-γ, and anti-CD40 antibody, but tumor-induced DC
paralysis could be reverted by a combination of CpGs and an
anti-IL-10R antibody (108).
The combination of signals promoting the immunostimula-
tory capacity of otherwise immunosuppressive DCs may depend
on different tumor settings. The use of agonistic anti-CD40 anti-
bodies as a single intervention has been successful at activating
tumor DCs to stimulate T cell rejection of a murine tumor
model (109). In addition, a fully human CD40 agonist anti-
body, CP-870,893, has been tested in humans with advanced
cancers, resulting in objective responses in 14% of patients (110).
However, mechanistic studies in preclinical models identified
macrophages as direct mediators of cytolytic anti-tumor activ-
ity, with negligible contribution of anti-tumor T cells (111).
Another trial using weekly dosing of CP-870,893 in advanced
cancer patients showed only stable disease as the best clini-
cal response. Some patients showed decreased T cell numbers,
indicating that the dosing interval may have been too frequent
(112). In our preclinical systems or in human tumor-derived
DCs, CD40 agonists alone had no measurable effect on DC
activation in vivo (34). However, based on the optimization of
multiple combinations of vaccine adjuvants carried out by Aho-
nen et al. (113), we confirmed that CD40 and TLR3 agonists
synergize to transform ovarian cancer-associated DCs from an
immunosuppressive to an immunostimulatory cell type, both
in vivo and in situ (34). These findings indicate the impor-
tance of acknowledging differences in the TME among vari-
ous cancers, including that treatments like CD40 agonists may
act on cells other than DCs. While in some tumors, CD40
agonists may singlehandedly activate DCs, in other tumors, like
ovarian carcinoma, combining CD40 agonists with TLR activation
will be necessary to revert DCs from immune-suppressors into
functional APCs.
The other component of our synergistic combination, TLR
agonists, can also activate DCs and has been tested in cancer
with some success as a monotherapy. TLR9 agonists, for
instance, have been developed and are in clinical trials (114).
Stronger stimulation of DCs can be achieved through the
activation of TLR3 with poly(I:C). To address its undesirable
toxicity in humans, a less stable version of poly(I:C) called
poly(I:C12U) was developed by incorporating a mismatched
uracil, which still functionally activates DCs and enhances their
IL-12 production (115).
Recent studies from our group have also underscored the
potential of immunostimulatory nanoparticles carrying func-
tional RNA against tumors that are compartmentalized, such
as ovarian cancer. We showed that nanocomplexes comprised
of polyethylenimine (PEI), a biocompatible polymer and TLR5
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agonist, and siRNA oligonucleotides targeting PD-L1 are selec-
tively engulfed by DCs in the ovarian cancer microenvironment
(32). Activation of multiple TLRs and PD-L1 silencing synergize
to promote the capacity of DCs at tumor locations to present
the tumor antigens that they spontaneously phagocytose in the
TME. Taking advantage of this optimized system, we were also able
to deliver immunostimulatory miR-155 specifically to immuno-
suppressive DCs in mouse ovarian tumors, through the use of
synthetic, functional double-stranded RNA Dicer substrates (37).
Augmenting miR-155 activity resulted in genome-wide transcrip-
tional changes that transformed DCs from a regulatory to an
immunostimulatory phenotype. Although human tumor ascites
primarily accumulates canonical macrophages, it is plausible that
miR-155 supplementation also exposes their capacity to effectively
present antigens. In addition, DCs are recruited to solid ovar-
ian cancer masses, where they accumulate at the growing edge,
in contact with ascites. Intra-peritoneal delivery of immunos-
timulatory nanocomplexes, therefore, offers significant promise
to reverse the immunosuppressive activity of ovarian cancer-
associated phagocytes. These approaches, however, need to be
clinically tested.
Finally, one method that harnesses the power of DCs is actually
a beneficial side effect of a classic treatment: chemotherapy. Cer-
tain chemotherapies are now understood to cause an immuno-
genic death of tumor cells that primes DCs to activate an anti-
tumor immune response. This mechanism was first described
for doxorubicin, showing that it induced immunogenic, caspase-
driven tumor cell death that stimulated a protective immune
response dependent on DCs and CD8 T cells (116). The features
of immunogenic cell death include the release of ATP (117), sur-
face exposure of calreticulin (118), and secretion of HMGB (119),
which respectively act to recruit (120), induce engulfment by (121),
and activate DCs for T cell stimulation. The list of agents inducing
immunogenic cell death has been extended to include anthra-
cyclines, oxaliplatin (but not cisplatin), and irradiation, among
others. For a recent comprehensive review, the reader is referred
to Kroemer et al. (122).
FINAL REMARKS
Pathological myelopoiesis in cancer individuals results in the accu-
mulation of a heterogeneous mix of MDSCs, macrophages, imma-
ture DCs, and regulatory DCs. This results in defective antigen pre-
sentation, which causes T cell anergy and, especially, exhaustion. In
addition, certain tumors mobilize classical DCs with immunosup-
pressive activity known as regulatory DCs. All these mechanisms
have hindered the success of DC-based vaccines. However, novel
approaches aiming to prevent tumor recurrences at early stages
or using DCs for ex vivo priming of tumor-reactive lymphocytes
offer significant promise. Finally, the antigen-presenting capacity
of tumor-infiltrating DCs can be promoted in vivo and in situ,
thus achieving the double goal of reversing immunosuppression
and directly boosting protective immunity.
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